
|Articles|April 27, 2015
Pharma's $462 Billion of M&As Since Jan 2014
Author(s)News Update
April 27, 2015.
Advertisement
Today's Financial Times (FT) reports
that, since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions - greater than the gross domestic product of Austria. In a piece entitled "No end in sight to wave of pharma dealmaking", and following the latest advances by Teva to make a bid for Mylan, Andrew Ward asks "What is driving the frenzy?" According to Jeremy Levin, former chief executive of Teva, the most impetus has been financial rather than strategic. For more on this story,
click here
.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook
2
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
3
Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff
4
FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo
5




